Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 29th Preview)
-
Phase 2-to-Phase 3 dose strategy for Merck’s heart failure drug
Merck is adjusting its development path for Winrevair (vericiguat/nearby class reference) in a pivotal Phase 3 trial after Phase 2 results showed its “pretty profound” benefit at the lowest tested dose. At ACC 26, Merck Chief Medical Officer Eliav shared that the company is leaning toward a lower dose in the Phase 3 program, aiming to preserve efficacy while optimizing the regimen. The update highlights how dose-finding readouts are being used to shape late-stage trial design for late-line cardiovascular therapies. For biopharma stakeholders, it underscores the practical leverage of Phase 2 dose-performance signals when planning registration-enabling studies. Merck’s next steps will depend on confirming the dose selection across a larger, more definitive patient population in Phase 3.
-
Biogen advances lupus immunology with Phase 2 win
Biogen reported Phase 2 success for litifilimab in lupus, positioning the anti-BDCA2 antibody as a potential pillar of its immunology pipeline. The company said the therapy improved skin lesions at 24 weeks, with 14.7% of patients reaching the prespecified skin-response endpoint. The readout strengthens Biogen’s case for continued clinical investment as it works toward later-stage studies and future regulatory engagement. For stakeholders, the focus is on whether the clinical signal in cutaneous lupus can translate into durable responses and broader outcomes beyond skin. Biogen’s next catalysts will be aligned with how it structures upcoming development decisions around the Phase 2 efficacy and safety profile.
-
Tanabe’s rare-disease strategy hits Phase 3 milestone
Tanabe Pharma disclosed positive Phase 3 data for an oral therapy targeting two rare diseases that cause pain when exposed to light. The company framed the result as its first major clinical milestone since the drugmaker’s acquisition by Bain Capital, putting the program back in focus for late-stage execution. The development matters for rare-disease investors because Phase 3 progress can accelerate downstream registration planning and strengthen negotiating leverage with payers and partners. Tanabe will likely use the dataset to guide the next steps in its regulatory timeline. The headline risk for the market will be how consistently the trial outcomes meet endpoints across the specific phenotype definitions for the two conditions.
-
Otsuka expands neuropsychiatric psychedelics pipeline via Transcend acquisition
Otsuka agreed to buy Transcend Therapeutics in a deal valued at about $1.2 billion, including roughly $700 million upfront, adding to a drug class designed to deliver psychedelic-like therapeutic benefits without the trip. The acquisition further consolidates Otsuka’s position in neuropsychiatric development. For the industry, the move signals continued payer- and regulator-facing investment in non-intoxicating mechanisms and differentiated CNS assets. Integration planning will determine how quickly Otsuka can advance Transcend’s programs toward pivotal readouts and potential label expansion. The market will watch the specific clinical programs inside Transcend that define the acquisition’s value and the expected path to late-stage catalysts.
-
EMA CHMP backs multiple drugs, including label and route changes
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines in March and also weighed in on label expansions for existing therapies. The update included CHMP backing for subcutaneous Sarclisa from Sanofi and recommendations affecting oncology and other therapeutic areas. CHMP actions can accelerate European market access and can also set the stage for payer negotiations and national reimbursement timelines. The panel’s decisions also reflected boundaries on expanded indications, including a rebuffed label expansion for Vanda’s Hetlioz in Smith-Magenis syndrome. For biopharma, these CHMP votes remain a key read on European regulators’ appetite for new indications and alternative formulations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.